Ovarian cancer is a frightening diagnosis that often comes after the cancer has spread. As a result, it’s the most deadly of the gynecological cancers. But not all the news about ovarian cancer is grim. Incidence is declining. Doctors are learning more about early symptoms and more effective treatments. The September issue of Mayo Clinic Women’s HealthSource looks at myths and facts about ovarian cancer. Myth: There are no early symptoms.

Two recent studies may provide improved insight into detecting ovarian cancer, one of the most deadly forms of the disease because it is difficult to catch in its earliest, most curable stages, the Wall Street Journal reports. In a

The U.S. Food and Drug Administration cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom. OVA1 identifies some women who will benefit from referral to a gynecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian cancer.

The U.S. Food and Drug Administration (FDA) cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy. The test was developed by Vermillion, Inc. (OTC: VRMLQ.

Centocor Ortho Biotech Products, L.P. announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer.

National Cancer Institute (NCI) has renewed a $11.5 million Specialized Program of Research Excellence (SPORE) grant in prevention, diagnosis and treatment of ovarian cancer, which supports multidisciplinary research at Fox Chase Cancer Center and the University of Pennsylvania. First approved in 1999, this marks the third five-year term for the Fox Chase-Penn Ovarian SPORE.

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company’s potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

A new genetic marker associated with ovarian cancer risk was recently discovered by an international research group, led by scientists from the Cancer Research Genetic Epidemiology Unit in the United Kingdom. Drs.

September is Ovarian Cancer Awareness Month. On Thursday, September 24th, fashion-savvy, budget-minded shoppers can support cancer research while receiving special savings on leading designer apparel for one day only, at any of the more than sixty Loehmann’s stores across the country.

In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. An initial study in patients conducted jointly by the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital has found that the treatment has no unwanted side-effects.